R/R MCL: long-term results of the MCL-002 SPRINT study

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In long-term follow-up of the phase 2 SPRINT study in patients with relapsed/refractory (R/R) mantle-cell lymphoma (MCL), single-agent lenalidomide maintained its significant PFS advantage vs investigator’s choice (IC, single-agent rituximab, gemcitabine, fludarabine, chlorambuci...